m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT02109
 [1]
m6A modification MIR670HG MIR670HG FXR1 : m6A sites Direct Enhancement DNA methylation TET1 CD24
m6A Modification:
m6A Regulator RNA-binding protein FXR1 (FXR1) READER
 Regulator Info 
m6A Target MIR670 host gene (MIR670HG)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type DNA methylation (DNAMeth)
Epigenetic Regulator Methylcytosine dioxygenase TET1 (TET1) ERASER View Details
Regulated Target CD24 molecule (CD24) View Details
Crosstalk Relationship m6A  →  DNA methylation Enhancement
Crosstalk Mechanism m6A modification directly impacts DNA methylation through recruiting DNA methyltransferases or demethylases.
Crosstalk Summary MIR670 host gene (MIR670HG) interacts with the m6A reader FXR1 and DNA 5-methylcytosine dioxygenase TET1 in an m6A modification-dependent manner. These interactions reduce the binding of TET1 to CD24 molecule (CD24) promoter, leading to increased DNA methylation at CD24 promoter and transcriptional suppression of CD24.
Responsed Disease Liver metastases ICD-11: 2D80
 Disease Info 
In-vivo Model To assess liver metastasis, indicated cells were intrasplenically injected into mice. At the indicated time, mice were euthanized, and livers were resected, fixed, and subjected to hematoxylin-eosin (HE) staining.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
CD24 molecule (CD24) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name BsAb cG7-MICA Investigative [2]
External Link
TTD: D0FZ7D
2D80: Liver metastases 4 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Contusugene ladenovec Phase 3 [3]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
External Link
TTD: D04FYL
 Compound Name Codrituzumab Phase 2 [4]
External Link
TTD: D0P0BY
 Compound Name DNX-2440 Phase 1 [5]
External Link
TTD: D28VIO
 Compound Name Anti-CEA CAR-T therapy Phase 1 [4]
External Link
TTD: D0OP1L
References
Ref 1 m(6)A-modified MIR670HG suppresses tumor liver metastasis through enhancing Kupffer cell phagocytosis. Cell Mol Life Sci. 2025 Apr 28;82(1):185. doi: 10.1007/s00018-025-05700-1.
Ref 2 Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008 Apr 15;68(8):2803-12.
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 ClinicalTrials.gov (NCT04714983) DNX-2440 for Resectable Colorectal Liver Metastasis. U.S. National Institutes of Health.